E7777 9 mcg/kg
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Conditions
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Trial Timeline
May 30, 2013 → Dec 14, 2021
NCT ID
NCT01871727About E7777 9 mcg/kg
E7777 9 mcg/kg is a phase 3 stage product being developed by Eisai for Persistent or Recurrent Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01871727. Target conditions include Persistent or Recurrent Cutaneous T-Cell Lymphoma.
What happened to similar drugs?
4 of 7 similar drugs in Persistent or Recurrent Cutaneous T-Cell Lymphoma were approved
Approved (4) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01871727 | Phase 3 | Completed |
Competing Products
20 competing products in Persistent or Recurrent Cutaneous T-Cell Lymphoma